Our Scientific Advisory Board (SAB)
John A. Lowe, III, Ph.D. obtained his Ph.D. degree at UCLA in 1977 in the
laboratories of Professor Michael E. Jung in synthetic organic chemistry in the area of
anthracycline anti-tumor antibiotics. He then did a postdoc with Professor William S.
Johnson at Stanford University in the area of polyene cyclization methodology for
the total synthesis of steroids. John began his 30-year career with Pfizer Inc. in 1979,
working in the antibiotics, antiiflammatory and CNS groups, where he identified key
structural elements of a new class of antipsychotic agents that led to the discovery of
the atypical antipsychotic drug ziprasidone, marketed as Geodon® in the US, with
2007 sales in excess of $800 million. In 1987, John joined a small team that initiated
Pfizer’s New Leads Group, where his work led to the discovery of the first potent,
non-peptide substance P (NK1) receptor antagonist, CP-96,345. Returning to the
CNS group, John worked on several projects, including cholecystokinin antagonists,
nitric oxide synthase inhibitors, and type 1 glycine transporter inhibitors.
John has authored 90 publications and presented 15 talks and posters at chemistry
and pharmacology meetings. He is an inventor or co-inventor on over 60 patents.
For his discovery of the drug Geodon®, John was awarded the 2005 Northeast
Regional Industrial Innovation Award, and the 2007 ACS Heroes of Chemistry Award.
He is the 2011 winner of the ACS Award in Industrial Chemistry. He chaired the 2006
Gordon Research Conference on Medicinal Chemistry, and since 2007, he has served
on the Scientific Advisory Board for the CHDI Foundation.
Lori V. Calabrese, M.D. received her B.A. in chemistry from Wellesley College
(Magna Cum Laude) in 1985 and her M.D. from Johns Hopkins University School of
Medicine in 1989. Dr. Calabrese did her internship in Medicine/Psychiatry at Francis
Scott Key Medical Center (Baltimore, 1989-90) and completed her Residencies in
Psychiatry at Mass. General Hospital (Boston, 1990-93). She has held teaching
positions at Harvard Medical School, Harvard Law School and Mass. General
Hospital. She was a Clinical Fellow and Instructor of Psychiatry at Harvard Medical
School (1990-2000) and has been an Assistant Clinical Professor of Psychiatry at
Yale School of Medicine since 2002. Dr. Calabrese has also held major committee
assignments at Johns Hopkins, Mass. General Hospital, Tewksbury (MA) Hospital,
the Massachusetts Psychiatric Society, the Connecticut Psychiatric Society and the
Department of Mental Health (Commonwealth of Massachusetts).
Dr. Calabrese has authored twelve peer-reviewed publications and has presented on
her clinical experiences at the 155th and 156th Annual Meetings of the APA.
She is licensed by the Connecticut Medical Board, and certified by the American
Board of Psychiatry & Neurology and the American College of Forensic Examiners.
Dr. Calabrese is a member of the American Medical Association (AMA), the American
Psychiatric Association (APA), the American Society of Clinical Psychopharmacology
(ASCP) and the American Academy of Clinical Psychiatry (ASCP). She was recognized
by Connecticut Magazine’s “Top Doctors: Best Physicians as Chosen by Their Peers”
in 2012 and 2013. Since 1997, Dr. Calabrese has operated her practice of General
Adult Psychiatry and Psychopharmacology in South Windsor, CT.
Jeffrey Sprouse, Ph.D. received his BA in Psychology / Chemistry from the
University of Delaware and his MS in Clinical Pharmacology at Penn State University
College of Medicine. In 1983, he earned his Doctorate in Pharmacology at the Joan
& Sanford I. Weill Medical College of Cornell University under Walter Riker, focusing
his research on drug-induced changes in the excitability of spinal roots. Following a
postdoctoral fellowship in Neuropharmacology with George Aghajanian at Yale
University School of Medicine (1984-1989), focused on functional studies of
serotonergic neurons of the dorsal raphe, Jeff took a position with the Merrell Dow
Research Institute as a Senior Research Pharmacologist (1989-1992). He
subsequently accepted a position at Pfizer’s Groton, CT research campus, where he
was responsible for in vitro and in vivo electrophysiological / behavior data
generation as a member of the Neurosciences Discovery department and was
directly responsible for the nomination of three unique clinical candidates. In 2007,
he left Pfizer as an Associate Research Fellow to join Lundbeck Research USA
(Paramus, NJ) where he was a leader of a psychiatry-based disease focus team
responsible for replenishing Lundbeck’s Exploratory Portfolio of new discovery
projects and for evaluating licensing opportunities and external collaborations. In
2010, Jeff formed Sprouse Consulting, LLC, drawing on his vast knowledge and
expertise as a scientist, portfolio manager and business development team member
to advise clients, typically small Pharma organizations, on the development of
product concepts and creation of a mechanistic message for potential partners. He
provides guidance on the management of discovery efforts, and has served as a
scientific liaison for preclinical CROs seeking business contacts within the
In 2013, Jeff created Cyanaptic, an early stage pharmaceutical company, to develop
new therapeutics to shape the impact of light on biological systems, targeting such
disorders as migraine and photophobia.
Dr. Sprouse is the author of more than fifty publications and is listed as an inventor
on seven US issued patents. His consulting business is located in Stonington, CT.